PMID- 12021110
OWN - NLM
STAT- MEDLINE
DCOM- 20020712
LR  - 20190616
IS  - 0077-8923 (Print)
IS  - 0077-8923 (Linking)
VI  - 958
DP  - 2002 Apr
TI  - Increased autoantibodies to SOX13 in Swedish patients with type 1 diabetes.
PG  - 218-23
AB  - This article aims to estimate the prevalence of SOX13 antibodies in Swedish 
      patients with type 1 diabetes and healthy controls. The patients (n = 102; median 
      age 35 years [range, 9-89]) were newly diagnosed with type 1 diabetes in a 
      defined area in southern Sweden during 1995-1998. Islet cell antibodies (ICA) 
      were analyzed with immunofluorescence, while glutamic acid decarboxylase 
      antibodies (GADA), tyrosine phosphatase antibodies (IA-2A), and antibodies 
      against the transcription factor SOX13 (SOX13Ab) were analyzed with 
      radioimmunoprecipitating assays. SOX13Ab were found in 9.8% (10/102) of type 1 
      patients compared to 2.0% (2/99) in healthy controls (P = 0.033). At least one of 
      the four autoantibodies (ICA, GADA, IA-2A or SOX13Ab) were identified in 67% 
      (68/102) of the patients. Samples positive for IA-2A were only in one case 
      positive also for SOX13Ab. IA-2A-positive patients were often positive also for 
      ICA and GADA (19/27), and the same combination was also common for 
      SOX13Ab-positive patients (6/10). Only 2.0% (2/102) were positive for SOX13Ab 
      alone. ICA, GADA and IA-2A were more frequent in younger patients (<or= 35 years 
      of age) than in older patients, while SOX13Ab showed similar frequency in both 
      groups. We concluded that the frequency of SOX13Ab was significantly increased in 
      Swedish patients with type 1 diabetes, but that the addition of SOX13Ab to the 
      combination of GADA and IA2-A only increased the sensitivity by 2% for autoimmune 
      diabetes. Therefore, SOX13 could be a minor autoantigen involved in the 
      pathogenesis of type 1 diabetes.
FAU - Torn, C
AU  - Torn C
AD  - Department of Medicine, University of Lund, Lund, Sweden. Carina.Torn@med.lu.se
FAU - Shtauvere-Brameus, A
AU  - Shtauvere-Brameus A
FAU - Sanjeevi, C B
AU  - Sanjeevi CB
FAU - Landin-Olsson, M
AU  - Landin-Olsson M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 0 (High Mobility Group Proteins)
RN  - 0 (SOX13 protein, human)
RN  - 0 (SOXD Transcription Factors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/immunology
MH  - Autoantibodies/blood/*immunology
MH  - Autoantigens/blood/*immunology
MH  - Child
MH  - Diabetes Mellitus, Type 1/epidemiology/*immunology
MH  - High Mobility Group Proteins/blood/*immunology
MH  - Humans
MH  - Middle Aged
MH  - SOXD Transcription Factors
MH  - Sweden/epidemiology
EDAT- 2002/05/22 10:00
MHDA- 2002/07/13 10:01
CRDT- 2002/05/22 10:00
PHST- 2002/05/22 10:00 [pubmed]
PHST- 2002/07/13 10:01 [medline]
PHST- 2002/05/22 10:00 [entrez]
AID - 10.1111/j.1749-6632.2002.tb02973.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2002 Apr;958:218-23. doi: 10.1111/j.1749-6632.2002.tb02973.x.